MedTrace Logo

NVG-291 in Spinal Cord Injury Subjects

NCT05965700 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-06

No results posted yet for this study

Summary

A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2a Study of NVG-291 in Spinal Cord Injury Subjects

Conditions

  • Spinal Cord Injuries
  • Chronic Spinal Cord Injury
  • Subacute Spinal Cord Injury

Interventions

DRUG

NVG-291

A once daily injection

Sponsors & Collaborators

  • NervGen Pharma

    lead INDUSTRY

Principal Investigators

  • Randall Kaye, M.D. · NervGen Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-08
Primary Completion
2026-03-31
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05965700 on ClinicalTrials.gov